Cargando…
Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy
BACKGROUND AND OBJECTIVES: Cladribine tablets cause a reduction in lymphocytes with a predominant effect on B-cell and T-cell counts. The MAGNIFY-MS substudy reports the dynamic changes on multiple peripheral blood mononuclear cell (PBMC) subtypes and immunoglobulin (Ig) levels over 12 months after...
Autores principales: | Wiendl, Heinz, Schmierer, Klaus, Hodgkinson, Suzanne, Derfuss, Tobias, Chan, Andrew, Sellebjerg, Finn, Achiron, Anat, Montalban, Xavier, Prat, Alexandre, De Stefano, Nicola, Barkhof, Frederik, Leocani, Letizia, Vermersch, Patrick, Chudecka, Anita, Mwape, Claire, Holmberg, Kristina H., Boschert, Ursula, Roy, Sanjeev |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679889/ https://www.ncbi.nlm.nih.gov/pubmed/36411081 http://dx.doi.org/10.1212/NXI.0000000000200048 |
Ejemplares similares
-
Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS
por: de Stefano, Nicola, et al.
Publicado: (2022) -
Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis
por: Schmierer, Klaus, et al.
Publicado: (2022) -
Expert opinion on the use of cladribine tablets in clinical practice
por: Sørensen, Per Soelberg, et al.
Publicado: (2020) -
Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets
por: Yamout, Bassem I, et al.
Publicado: (2022) -
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
por: Rieckmann, Peter, et al.
Publicado: (2021)